International Journal of Research and Review
Vol. 9; Issue: 9; September 2022
Website: www.ijrrjournal.com
E-ISSN: 2349-9788; P-ISSN: 2454-2237
Original Research Article
Use of Daily Low-Dose Aspirin in Pregnancy for
Women at High Risk of Preeclampsia at
Georgetown Public Hospital Corporation
Dr. Sabrina Gittens1, Dr. Janie Pak2
1
Georgetown Public Hospital Corporation, East and New Market Street Georgetown, Guyana
Kaiser Permanente San Diego Medical Center, 9455 Clairemont Mesa Blvd, San Diego, California,
United States
2
Corresponding Author: Dr. Sabrina Gittens
DOI: https://doi.org/10.52403/ijrr.20220937
ABSTRACT
Objective: To Determine what proportion of
eligible high-risk women diagnosed with
preeclampsia received low dose aspirin during
antepartum care.
Design & Methods: This was a retrospective
chart review of all patients who delivered at
Georgetown Public Hospital Corporation
between September to December 2017 and were
diagnosed with a hypertensive disorder in
pregnancy. The primary outcome was the
fraction of women diagnosed with preeclampsia,
eclampsia or HELLP syndrome who met the
U.S. Preventive Task Force criteria to be started
on aspirin and were started on aspirin between
12 and 28 weeks of gestation. Maternal
secondary outcomes included: Intensive care
unit admissions, end organ injury, placental
abruption and death. Neonatal secondary
outcomes included: Neonatal intensive care unit
admissions, fetal growth restriction, preterm
births, stillbirths and neonatal death. Data was
organised and analysed in Microsoft Excel
2016.
Results: Of the 2,452 deliveries, 2,160 (88%)
charts were found and reviewed. 14.3% were
diagnosed with a hypertensive disorder in
pregnancy. Of these, 37% had preeclampsia,
eclampsia or HELLP syndrome. Among these,
36.8% met criteria to receive low dose aspirin
antepartum but only 4.8% received aspirin. Of
the secondary outcomes, one death occurred
because of a haemorrhagic CVA. 42.1% of
neonates were born prematurely of which 4
were stillbirths and 4 were neonatal deaths.
Conclusions; The routine use of a low dose of
aspirin among pregnant women who met the
criteria to be started on was low.
Recommendations: All women should be
screened for the risk of developing preeclampsia
and if needed, aspirin should be started between
12-28 weeks of gestation to get the best effects.
Key Words: preeclampsia, aspirin in pregnancy,
GPHC
INTRODUCTION
Hypertensive disorders in pregnancy is one
of the leading cause of maternal deaths with
99% of them occurring in developing
Risk
factors
strongly
countries.[1,2]
predisposing pregnant women to developing
preeclampsia
include:
history
of
preeclampsia, multifetal gestation, chronic
hypertension, Type 1 or 2 diabetes, renal
disease, and autoimmune diseases.[3-7] A
wide array of serious complications can
arise from preeclampsia including HELLP
syndrome (Hemolysis, Elevated Liver
enzymes
and
Low
Platelets),
cerebrovascular accident (CVA), kidney
injury, pulmonary oedema, placental
abruption, intrauterine growth restriction
(IUGR), fetal and maternal demise.[2,7] Daily
use of low dose aspirin has been shown to
significantly decrease the risk of developing
preeclampsia, preterm birth, and IUGR in
women at high risk for preeclampsia and
should be offered to them in their second
International Journal of Research and Review (ijrrjournal.com)
Vol. 9; Issue: 9; September 2022
339
Dr. Sabrina Gittens et.al. Use of daily low-dose aspirin in pregnancy for women at high risk of preeclampsia at
Georgetown Public Hospital Corporation
trimester. [8-14] Unlike prior belief, the daily
use of a low dose of an antiplatelet agent
(aspirin) has not been shown to cause any
significant change or abnormal bleeding
time values. [15] Although preeclampsia is a
leading cause of maternal morbidity and
mortality in Guyana, many high-risk women
are not offered aspirin in their second
trimester despite its benefits. Low dose
aspirin is easily accessible and affordable
but the lack of knowledge or fear of its use
during pregnancy may be barriers to
providers prescribing it to high risk women.
The impact of these missed opportunities is
largely unknown as no studies have been
done to measure it.
Having a knowledge of baseline practices at
the
Georgetown
Public
Hospital
Corporation (GPHC), the primary referral
hospital, can guide interventions focused on
educating health care professionals to help
reduce the risk of one of the most serious
and common disorders in pregnancy for
both mother and baby. The objective of this
study was to determine the proportion of
eligible high-risk women diagnosed with
preeclampsia who received low dose of
aspirin during their antepartum care using
the US Preventive Services Task Force
criteria (USPSTF) (Table 9).
MATERIALS AND METHODS
This was a retrospective, observational
descriptive study involving a chart review of
all patients who delivered at GPHC from
September 1st to December 31st 2017. The
charts of all patients who were diagnosed
with a hypertensive disorder in pregnancy
including preeclampsia, eclampsia or
HELLP syndrome, gestational hypertension
(GHTN), chronic hypertension (CHTN) and
chronic hypertension with superimposed
preeclampsia (CHTN with SIP) were
included in this study. All other charts were
excluded. Basic demographic information
including age, race, marital status, region of
residence (the 10 administrative regions are
depicted below with an arrow focusing on
the region with most of the population and
the capital city - region 4), antenatal clinic
(ANC), gestational age at diagnosis, referral
information, and gestational age on
admission to GPHC were collected.
Figure 1: Map of Administrative Division of Guyana
https://commons.wikimedia.org/wiki/File:Guyana,_administrative_divisions_-_Nmbrs_-_colored.svg
https://upload.wikimedia.org/wikipedia/commons/f/fd/Guyana%2C_administrative_divisions_-_Nmbrs_-_colored.svg
TUBS, CC BY-SA 3.0 <https://creativecommons.org/licenses/by-sa/3.0>, via Wikimedia Commons
International Journal of Research and Review (ijrrjournal.com)
Vol. 9; Issue: 9; September 2022
340
Dr. Sabrina Gittens et.al. Use of daily low-dose aspirin in pregnancy for women at high risk of preeclampsia at
Georgetown Public Hospital Corporation
There was a total of 2,452 deliveries
between September 1st, 2017 and December
31st, 2017 at GPHC. 2,160 of the 2,452
(88.1%) were reviewed. The remainder of
the charts could not be located. Of the 2,160
patients, 308 (14.3%) were diagnosed with a
hypertensive disorder of pregnancy and
included in this study.
The medical charts were reviewed to
determine how many of these women were
eligible to receive prenatal aspirin by either
having at least one strong risk factor or
more than or equal to three moderate risk
factors for preeclampsia according to the
USPSTF criteria. Strong risk factors
included: history of preeclampsia especially
when accompanied by an adverse outcome,
multifetal gestation, chronic hypertension,
Type 1 or 2 diabetes, renal disease, or
autoimmune diseases. Moderate risk factors
included: nulliparity, obesity (body mass
index (BMI) >30 kg/m2), family history of
preeclampsia
(mother
or
sister),
sociodemographic characteristics, more than
or equal to 35 years of age, personal history
factors (Table 9).
The primary outcome of interest was to
determine the proportion of eligible women
diagnosed with preeclampsia, eclampsia or
HELLP syndrome who met USPSTF
criteria to start prenatal low-dose aspirin and
actually received this therapy between 12
and 28 weeks of gestation. Secondary
maternal outcomes of interest included:
maternal intensive care unit (ICU)
admissions, end organ injury, abruption and
death. Secondary neonatal outcomes
included: intrauterine fetal demise (IUFD),
IUGR, preterm birth and associated early
neonatal comorbidities and stillbirths among
women diagnosed with preeclampsia. This
study was approved by the Institutional
Review Board within the Ministry of Public
Health of Guyana and by the research
committee at GPHC. Data was collected and
analyzed using Microsoft Excel 2016.
STATISTICAL METHODS
Being a descriptive observational study,
measures of frequency (count and percent)
and central tendency (mean and mode) were
described.
RESULTS
Table 1 summarizes
the
demographic
information for the 308 of the 2,160 patients
diagnosed with a hypertensive disorder.
Ages ranged from 14 to 42 with an average
of 27. The most prevalent race was African
at 37.7% (n = 43). 41.2% (n = 47) were in a
Common-law relationship and more than
half (54.39 %, n=62) resided in region 4
[Figure 1].
Number
Percentage
Age group
18 and under
10
8.8%
19-25
46
40.4%
26-30
16
14.0%
31-34
18
15.8%
>/= to 35
24
21.1%
Total
114
100.0%
Race
African
43
37.7%
Mixed
34
29.8%
East Indian
18
15.8%
Amerindian
18
15.8%
Not stated
1
0.9%
Total
114
100.00%
Marital status
Common-Law
47
41.2%
Single
33
29.0%
Married
30
26.3%
Not stated
4
3.5%
Total
114
100.00%
Region
4
62
54.4%
3
21
18.4%
1
11
9.7%
6
7
6.1%
10
3
2.6%
5
3
2.6%
7
3
2.6%
2
2
1.8%
8
1
0.9%
9
1
0.9%
Total
114
100.00%
Table 1: Demographic information of all patients diagnosed
with a hypertensive disorder in pregnancy
Table 2 shows the gestational ages at the
first ANC visit. Of the 114 patients with
preeclampsia, eclampsia or HELLP
syndrome, 40 patients’ antenatal history was
not found or recorded. The remaining 74
patients had an average of 7.3 antenatal
visits. 78.1% (n = 89) were referred to
GPHC, at an average gestational age of 35
weeks. At the time of referral, 88.8% (n=79)
were after 28 weeks of gestation, beyond the
International Journal of Research and Review (ijrrjournal.com)
Vol. 9; Issue: 9; September 2022
341
Dr. Sabrina Gittens et.al. Use of daily low-dose aspirin in pregnancy for women at high risk of preeclampsia at
Georgetown Public Hospital Corporation
gestational age at which
recommend starting aspirin.
guidelines
Gestational Age
GA at first ANC
Number %
< 12 weeks*
18
15.8%
12 0/7 to 19 6/7
35
30.7%
20 0/7 to 27 6/7
13
11.4%
28 0/7 to 33 6/7
4
3.5%
34 0/7 to 36 6/7
3
2.6%
37 and above
Post-partum
Not seen
41
36%
Grand Total
114
100%
Table 2: Gestational age at diagnosis and first antenatal clinic
visit
GA - gestational age
ANC - antenatal clinic
36.8% (n=42) of the women diagnosed with
a hypertensive disorder were candidates for
low dose aspirin based on varying risk
factors (Table 3) of which only two actually
received aspirin (4.8%). The most common
strong risk factors were CHTN (18.4%,
n=21) and a history of preeclampsia (15.8%,
n=18). The most common moderate risk
factors were nulliparity (38.6%, n=44),
African race (37.7%, n=43), age equal to or
above 35 years (21%, n=24) and obesity
(15.8%, n=18). Of the two women who
received aspirin, one was started at 22
weeks 3 days and the other at 33 weeks 6
days. These findings reflect the primary
outcome of the study.
Number
High Risk factors
Chronic hypertension
21
History of preeclampsia
18
Renal disease
1 (CRF)
Autoimmune disease
1 (Goitre)
Multifetal gestation
0
Type 1 or 2 diabetes
0
Moderate risk factors
Nulliparity
44
Sociodemographic
43 (African)
characteristics
Age ≥35 years
24
Obesity (BMI > 30kg/m2)
18 §
Personal history factors
8 PTD (7 died)
Percentage
18.4 %
15.8 %
0.9 %
0.9 %
0.0 %
0.0 %
38.6 %
37.7 %
21 %
15.8 %
7 % (6.1%
died)
1.6 %
Family
history
of 2
preeclampsia
Table 3: Risk factors for Preeclampsia
BMI - body mass index calculated as Kg per m2 - §
for 64 patients was not recorded/done.
CRF - chronic renal failure
PTD - preterm delivery
The average gestational age at delivery was
37 weeks. The average weight at delivery
was 2622g (Table 4). A 5- minute APGAR
score of 7 or less was seen in 14.9% (n =
17) neonates of which only two were at
term. The APGAR score was unknown for 3
patients due to inability to find the charts.
There was a total of 4 neonatal deaths and 4
stillbirths (3.5% each). 6.1% (n = 7)
neonatal outcomes were unknown due to the
inability to find the charts. All but one of
these deaths were in preterm neonates. The
cause of death was documented for only one
of the neonates and was noted to be as a
result of haemorrhagic shock. Of the 86.8%
(n=99) neonates that were alive with a
documented chart, 36.6% (n = 36) had more
than or equal to one of the following:
respiratory distress syndrome, sepsis and
pneumonia.
Gestational age
Less than 28
Between 28 and 32
Between 32 and 34
Between 34 and 37
> 37
GA unknown
Grand Total
Neonatal Weight
Less than 1000g
Between 1000 and 1500g
Between 1500 and 2000g
Between 2000 and 2500g
Between 2500 and 3000g
Over 3000g
Unknown
Grand Total
Days of admission
1 to 3 days
4 to 6 days
7 to 9 days
10 to 14 days
>/= 15 days
Unknown
Grand Total
Number
2
8
9
29
65
1
114
%
1.8%
7%
7.9%
25.4%
57%
0.9%
100%
4
6
8
20
28
38
10
114
3.5%
5.3%
7%
17.5%
24.6%
33.3%
8.8%
100%
74
12
6
5
9
8
114
65%
10.5%
5.3%
4.4%
7.9%
7%
100%
Table 4: Neonatal outcomes
54.4% (n = 62) of the women delivered
vaginally and 45.6% (n = 52) by cesarean
delivery. 27.2% (n = 31) with the
hypertensive diagnosis within the indication
for cesarean. 54.4% (n = 62) had induction
or augmentation of labour. Table 5 shows
details of labour induction and delivery
details including mode and estimated blood
loss (EBL) and days of admission.
International Journal of Research and Review (ijrrjournal.com)
Vol. 9; Issue: 9; September 2022
342
Dr. Sabrina Gittens et.al. Use of daily low-dose aspirin in pregnancy for women at high risk of preeclampsia at
Georgetown Public Hospital Corporation
Indication for CD
NRFHT
Eclampsia
Failed IOL (HTN)
HTN
HTN & Breech
HTN & NRFHT
HTN & LSCS
HTN & ROM-(Mec)
LSCS
LSCS & Other
Other
Number
15
4
4
8
1
5
8
1
1
2
3
52
%
13.2%
3.5%
3.5%
7%
0.9%
4.4%
7%
0.9%
0.9%
1.8%
2.6%
45.6%
Total
Induction or Augmentation of labour
IOL/AOL
Number
%
AOL
4
3.5%
IOL
49
43%
IOL + AOL
9
7.9%
No
51
44.7%
Unknown
1
0.9%
Total 114
100%
Indication for IOL/AOL
Number
%
CHTN
1
0.9%
CHTN r/o SIP
3
2.6%
CHTN+SIP
6
5.3%
Eclampsia
3
2.6%
GHTN
6
5.3%
GHTN r/o PEC
1
0.9%
MPEC
9
7.9%
PROM
1
0.9%
SPEC
36
31.6%
N/A
47
41.3%
Unknown
1
0.9%
Total
114
100%
EBL
Number
%
>/=1000
6
5.3%
500 to 1000
14
12.3%
Less than 500
94
82.5%
Total
114
100%
Days of admission
Number
%
>/=21 days
3
2.6%
1 to 5 days
67
58.8%
11 to 15 days
6
5.3%
16 to 20 days
2
1.8%
6 to 10 days
29
25.4%
Unknown
7
6.1%
Total
114
100%
Table 5: Maternal outcome and delivery details
CD - cesarean delivery
LSCS -lower segment cesarean section
IOL - induction of labour
AOL - augmentation of labour
NRFHT - non-reassuring fetal heart tracing
ROM - rupture of membranes: Mec - meconium
PROM - prelabour/premature rupture of membranes
EBL - estimated blood loss
IOL – induction of labour
AOL – augmentation of labour
CHTN - chronic hypertension
CHTN r/o SIP - chronic hypertension rule out superimposed preeclampsia
GHTN - gestational hypertension
MPEC - mild preeclampsia (preeclampsia without severe features)
SPEC - severe preeclampsia (preeclampsia with severe features)
N/A - not applicable
Table 6, 7 and 8 summarises the maternal
complications, blood pressure ranges and.
abnormal laboratory results respectively.
1.8% (n = 2) were diagnosed with HELLP
International Journal of Research and Review (ijrrjournal.com)
Vol. 9; Issue: 9; September 2022
343
Dr. Sabrina Gittens et.al. Use of daily low-dose aspirin in pregnancy for women at high risk of preeclampsia at
Georgetown Public Hospital Corporation
syndrome. 7.9% (n = 9) were admitted to
the Intensive care unit (ICU), 3.5% (n = 4)
with eclampsia, 3.5% (n = 4) with
preeclampsia with severe features and 0.9%
(n = 1) with CHTN with SIP. One of the
patients admitted to ICU died on post-
partum day 5 secondary to haemorrhagic
CVA (one with eclampsia). 52.6% (n = 60)
required the use of antihypertensives during
the antepartum period (51 with single drug
use and 9 with use of two drugs).
Admitted to ICU
Complication
Number Percentage
ARDS secondary to CAP
1
0.9%
Bilateral mild uretero-hydronephrosis
1
0.9%
Haemorrhagic CVA = died
1
0.9%
Pleural effusion, pericardial effusion
1
0.9%
Pulmonary embolism, atypical pneumonia
1
0.9%
Pulmonary edema
1
0.9%
R/o Cardiomyopathy, hyperkalemia, AKI
1
0.9%
R/o Intracranial hemorrhage
1
0.9%
Total
8
7.2%
Not admitted to ICU
Complication
Number Percentage
AVM
1
0.9%
PPH
1
0.9%
PPH - cervical laceration
1
0.9%
R/o intracranial hemorrhage
1
0.9%
Total
4
3.6%
Table 6: Maternal Complications for patients that were and were not admitted to ICU
ARDS - acute respiratory distress syndrome.
CAP -community acquired pneumonia
CVA - cerebrovascular accident
AKI - acute kidney injury
AVM - arterio-venous malformation
PPH – post-partum haemorrhage
Number
Percentage
Severe range:
93
81.6%
>/= 160 systolic or
>/=110 diastolic
Mild to moderate range:
19
16.7%
140-149 systolic or
90-99 diastolic
Table 7: Blood Pressure Ranges
Parameter
Number
Hb < 7mg/dL
3
PLT < 150 109/L
3
PLT < 100 109/L
1
PLT < 50 109/L
2
LDH> 500
1
LDH> 1000
1
AST/ALT > double upper limit
4
Creatinine > 1.1 mg/dL
35
Table 8: Laboratory Findings
Percentage
2.6%
2.6%
0.9%
1.8%
0.9%
0.9%
3.5%
30.7%
Hb - haemoglobin.
PLT - platelet
LDH - lactate dehydrogenase.
AST/ALT - aspartate aminotransferase/ alanine
aminotransferase
DISCUSSION
The updated USPSTF guidelines now
recommends starting a low-dose of aspirin
after 12 weeks but before 28 weeks of
gestation for eligible high-risk patients. [10,11]
Daily use of low dose aspirin has been
shown to significantly decrease the risk of
preeclampsia, preterm birth, and IUGR in
women at high risk for preeclampsia and
should be offered to them in their second
trimester. [11,12,13] The daily use of a low
dose of an antiplatelet agent (aspirin) has
not been shown to cause any significant
change or abnormal bleeding time values
unlike prior belief. [15] Daily use of low dose
aspirin is also recommended by the Royal
College of Obstetricians and Gynaecologists
(RCOG). [16]
The prevalence of hypertensive disorder in
pregnancy for this time period of four
months was above the worldwide
prevalence (14.3% vs 5.2-8.2%), [6] however
that of preeclampsia (5.3%) was consistent
with reported global prevalence of 0.29.2%. [6] The vast majority of the women
(95.2%, n = 40) that should have been
started on a daily low dose of aspirin were
International Journal of Research and Review (ijrrjournal.com)
Vol. 9; Issue: 9; September 2022
344
Dr. Sabrina Gittens et.al. Use of daily low-dose aspirin in pregnancy for women at high risk of preeclampsia at
Georgetown Public Hospital Corporation
not started. Most (88.8%) of the women
referred to GPHC - the main referral
hospital located in the capital city of
Georgetown in region 4 [Figure 1] - were
referred after the gestational age at which
aspirin should be started. And 1 of the 2
patients who were started on aspirin was
actually started later than the recommended
28 weeks upper limit. This could be due to
inadequate knowledge about the current and
updated guidelines, mostly in the outlying
regions. The majority of patients seen first
join an antenatal clinic with an advanced
gestational age, above the time for aspirin to
have the best effect (between 12 to 28
weeks of gestation). This should indicate the
need for continued education and updating
of our health care professionals on new
practices mostly at the primary health care
facilities, but also for new and rotating staff
at the secondary and tertiary systems.
The strengths of the study included that the
information was collected from the period
of the year with the most deliveries which
gives a general representation of the hospital
as well as Guyana. The time period of the
study was only 4 months due to a time
constraint, and the incidences were only for
that period. These 4 months however,
corresponded to the “peak” season.
(Deliveries for 2017 total-6164 and
deliveries corresponding to these 4 months 2452 [39.8%]). Also, a good idea of the
kinds of, and most prevalent risk factors
present among our population was obtained.
This was the first study of it’s kind in
Guyana.
Limitations included that only the
information for 2160 of the 2542 deliveries
for this period was collected. This was
because of the inability to find the medical
charts. Hence, the incidence of preeclampsia
and hypertensive disorders in pregnancy on
a whole was not truly reflected. On this
same note all the information for some of
the neonates were not seen because the
charts were not found, as well as some of
the information from the chart of one of the
mothers. Documentation in terms of
antenatal clinic visits were not copied or
recorded in all charts, hence the details
related to time of diagnosis and number of
clinic visits could not be found. All of this
information could not be gathered for one
patient because these details were not seen
in the chart. Documentation of other
information such as BMI parameters was
not done for all patients and others such as
vital records as well as drug records were
not seen.
Women should be encouraged to join ANC
early in pregnancy, not only to be screened
for risk of developing preeclampsia, but for
other health concerns in order to optimize
their health in pregnancy and after as well.
And for this same reason obtain routine
ANC visits in an adequate amount. Because
of the prevalence and consequences of
preeclampsia, all women should be screened
and if needed, aspirin started between 12-28
to get the best effects. Continuous medical
education and updates on high risk
pathologies, should be routinely performed
for the staff at GPHC as well as, and
especially for the outlying regions.
CONCLUSIONS
The most common high risk factors that
were found included CHTN and a history of
preeclampsia, while the most common
moderate risk factors were nulliparity,
African race, age equal to or above 35
years and obesity. The use of aspirin to
reduce the risk of developing preeclampsia
for these patients was insufficient at only
4.8%. Both cases were started beyond the
recommended initial gestational age to have
the best effect. A large part of this could
possibly be attributed to the lack of
knowledge of this practice, principally
among the outlying regions.
Acknowledgments: Mathew Miller,
Natasha France, Hardeo Ramdeholl
Conflict of Interest: None
Source of Funding: None
International Journal of Research and Review (ijrrjournal.com)
Vol. 9; Issue: 9; September 2022
345
Dr. Sabrina Gittens et.al. Use of daily low-dose aspirin in pregnancy for women at high risk of preeclampsia at
Georgetown Public Hospital Corporation
REFERENCES
1. World Health Organization (WHO).
Maternal Mortality [Internet]; 2019,
September 9 [Cited 2019, October 1]
Available
from: https://www.who.int/en/newsroom/fact-sheets/detail/maternal-mortality.
2. DULEY L: Maternal mortality associated
with hypertensive disorders of pregnancy in
Africa, Asia, Latin America and the
Caribbean. BJOG: An International Journal
of Obstetrics and Gynaecology. 1992; 99
(7):547-53.
doi:
10.1111/j.14710528.1992.tb13818.x
3. Bartsch E, Medcalf KE, Park AL, Ray
JG: Clinical risk factors for pre-eclampsia
determined in early pregnancy: systematic
review and meta-analysis of large cohort
studies. BMJ. 2016; 353:i1753. doi:
10.1136/bmj.i1753
4. Hernández-Díaz S, Toh S, Cnattingius
S: Risk of pre-eclampsia in first and
subsequent pregnancies: prospective cohort
study.
BMJ.
2009;
338:b2255.
doi: 10.1136/bmj.b2255
5. Surapaneni T, Bada VP, Nirmalan CP: Risk
for Recurrence of Pre-eclampsia in the
Subsequent Pregnancy. J Clin Diagn Res.
2013;
7
(12):2889-2891. doi:
10.7860/JCDR/2013/7681.3785
6. Umesawa M, Kobashi G: Epidemiology of
hypertensive disorders in pregnancy:
prevalence, risk factors, predictors and
prognosis. Hypertens Res. 2016; 40:213220. 10.1038/hr.2016.126
7. Cunningham FG, Leveno KJ Bloom SL,
Spong CY, Dashe JS, Hoffman BL,
Sheffield J. Williams obstetrics. 24th ed.
New York: Mcgraw-Hill Education; 2014.
p736-779
8. Imperiale TF: A Meta-analysis of LowDose Aspirin for the Prevention of
Pregnancy-Induced Hypertensive Disease.
JAMA: The Journal of the American
Medical Association. 1991; 10 (2):260-264.
doi: 10.1001/jama.1991.03470020086038
9. Duley L, Meher S, Hunter KE, et
al.: Antiplatelet agents for preventing preeclampsia and its complications. Cochrane
Database of Systematic Reviews. 2019;
30:18.
doi: 10.1002/14651858.cd004659.pub3
10. USPSTF. Archived: Low-Dose Aspirin Use
for the Prevention of Morbidity and
Mortality From Preeclampsia: Preventative
11.
12.
13.
14.
15.
16.
Medication [Internet]. 2014, September 9.
[Cited 2017, September 10]. Available
from:
https://www.uspreventiveservicestaskforce.
org/uspstf/recommendation/low-doseaspirin-use-for-the-prevention-of-morbidityand-mortality-from-preeclampsiapreventive-medication-september-2014
Henderson JT, Whitlock EP, O’Connor E, et
al.: Low-Dose Aspirin for Prevention of
Morbidity
and
Mortality
From
Preeclampsia: A Systematic Evidence
Review for the U.S. Preventive Services
Task Force. Annals of Internal Medicine.
2014, 160:695-703. doi: 10.7326/M13-2844
LeFevre ML: Low-Dose Aspirin Use for the
Prevention of Morbidity and Mortality From
Preeclampsia: U.S. Preventive Services
Task Force Recommendation Statement.
Annals of Internal Medicine. 2014,
161:819-826. doi: 10.7326/M14-1884
Bujold E, Roberge S, Lacasse Y, et
al.: Prevention of
preeclampsia and
intrauterine growth restriction with aspirin
started in early pregnancy: a meta-analysis.
Obstetrics and gynecology. 2010; 116 (2
part
1):402-414.
doi: 10.1097/AOG.0b013e3181e9322a
ACOG: Low-Dose Aspirin Use During
Pregnancy [Internet]. 2018, July. [Cited
2018, October 10]. Available from:
https://www.acog.org/clinical/clinicalguidance/committeeopinion/articles/2018/07/low-dose-aspirinuse-during-pregnancy
Williams HD, Howard R, O’Donnell N,
Findley I: The effect of low dose aspirin on
bleeding times. Anaesthesia. 1993; 48
(4):331-333.
doi: 10.1111/j.13652044.1993.tb06956.x
National Collaborating Centre for Women's
and Children's Health (UK: Hypertension in
Pregnancy:
The
Management
of
Hypertensive Disorders During Pregnancy.
RCOG Press.. PubMed.gov . 2010
How to cite this article: Sabrina Gittens, Janie
Pak. Use of daily low-dose aspirin in pregnancy
for women at high risk of preeclampsia at
Georgetown Public Hospital Corporation.
International Journal of Research and Review.
2022; 9(9): 339-347. DOI: https://doi.org/
10.52403/ijrr.20220937
International Journal of Research and Review (ijrrjournal.com)
Vol. 9; Issue: 9; September 2022
346
Dr. Sabrina Gittens et.al. Use of daily low-dose aspirin in pregnancy for women at high risk of preeclampsia at
Georgetown Public Hospital Corporation
APPENDIX
Risk
Level
High†
Moderate‡
Low
Risk Factors
Recommendation
History of preeclampsia, especially when accompanied by an adverse Recommend low-dose aspirin if the patient has
outcome;
≥1 of these high-risk factors
Multifetal gestation;
Chronic hypertension;
Type 1 or 2 diabetes;
Renal disease;
Autoimmune disease (systemic lupus erythematous, antiphospholipid
syndrome)
Nulliparity;
Consider low-dose aspirin if the patient has
Obesity (body mass index >30 kg/m2);
several of these moderate-risk factors§
Family history of preeclampsia (mother or sister);
Sociodemographic characteristics (African American race, low
socioeconomic status); Age ≥35 years;
Personal history factors (e.g., low birth weight or small for gestational age,
previous adverse pregnancy outcome, >10-year pregnancy interval)
Previous uncomplicated full-term delivery
Do not recommend low-dose aspirin
Table 9: Clinical Risk Assessment for Preeclampsia*USPSTF Criteria
* Includes only risk factors that can be obtained from the patient medical history. Clinical measures, such as
uterine artery Doppler ultrasonography, are not included.
† Single risk factors that are consistently associated with the greatest risk for preeclampsia. The preeclampsia
incidence rate would be approximately ≥8% in a pregnant woman with ≥1 of these risk factors.
‡ A combination of multiple moderate-risk factors may be used by clinicians to identify women at high risk for
preeclampsia. These risk factors are independently associated with moderate risk for preeclampsia, some more
consistently than others1.
§ Moderate-risk factors vary in their association with increased risk for preeclampsia.
******
International Journal of Research and Review (ijrrjournal.com)
Vol. 9; Issue: 9; September 2022
347